Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab/trastuzumab - Roche

Drug Profile

Pertuzumab/trastuzumab - Roche

Alternative Names: Herceptin/perjeta; Perjeta/herceptin; RG 6264; Trastuzumab/pertuzumab

Latest Information Update: 26 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer International Breast Cancer Study Group; Merck & Co; Roche
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Breast cancer

Most Recent Events

  • 25 Feb 2020 Preregistration for Breast cancer (Combination therapy, Early-stage disease) in USA (SC)
  • 24 Feb 2020 The US FDA will decide for the BLA approval for pertuzumab/trastuzumab by October-18-2020
  • 14 Jan 2020 Roche announces intention to submit regulatory applications to the US FDA and EMA for Breast cancer (Combination therapy) in Q1 of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top